Medlive Technology Co., Ltd. — Board/Management Information 2023

Apr 14, 2023

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [119 x 52] intentionally omitted <==

Medlive Technology Co., Ltd. 醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the “ Board ”) of Medlive Technology Co., Ltd. (the “ Company ”, together with its subsidiaries, the “ Group ”) announces that Dr. Li Zhuolin (“ Dr. Li ”) has tendered his resignation as a non-executive director of the Company with effect from 14 April 2023 as he intended to devote more time to his other business commitments.

Dr. Li confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”).

The Board would like to take this opportunity to express its sincere gratitude to Dr. Li for his valuable contributions to the Company during his tenure of office.

The Board is pleased to announce that Mr. Kazutaka Kanairo (“ Mr. Kanairo ”) has been appointed as a non-executive Director of the Company with effect from 14 April 2023.

Background of Mr. Kanairo

Mr. Kazutaka Kanairo (金色一賢), aged 45, is the head of India & Southeast Asia business and director of global corporate development of M3, Inc. (a company listed on the Tokyo Stock Exchange (Stock Code: 2413.T) and one of the controlling shareholders of the Company). Prior to joining M3, Inc. in March 2014, Mr. Kanairo worked at McKinsey & Company, Inc. from April 2003 to August 2008, where his last position was associate. From July 2010 to February 2014, Mr. Kanairo worked at JPMorgan Securities Japan Co., Ltd. where his last position was associate. Mr. Kanairo has over twelve years of experience in M&A and corporate development and over eleven years of experience in management advisory.

– 1 –

Mr. Kanairo received his bachelor’s degree with a major in aeronautics and astronautics engineering and master’s degree with a major in aeronautics and astronautics engineering from the University of Tokyo in Japan in March 2001 and March 2003, respectively. Mr. Kanairo obtained his MBA degree from University of California, Berkeley in the United States in May 2010.

Mr. Kanairo does not hold any positions with the Company and other members of the Group and he has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement, and save as disclosed above, Mr. Kanairo has no other relationship with any Director, senior management or substantial or controlling shareholders (each as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”)) of the Company.

Mr. Kanairo entered into an appointment letter with the Company for a term of office of three years subject to the relevant provisions of retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Articles of Association of the Company and the Listing Rules. Under the terms of the appointment letter, Mr. Kanairo is not entitled to receive any remuneration from the Company.

As at the date of this announcement, Mr. Kanairo does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of Hong Kong laws).

General

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Kanairo as a non-executive Director of the Company that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

By order of the Board Medlive Technology Co., Ltd. Tian Liping Chairwoman and Chief Executive Officer

Hong Kong, 14 April 2023

As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.

– 2 –